Abstract
Cross-sectional studies suggest that obstructive sleep apnea (OSA) is a potential risk factor for incident COVID-19 infection, but longitudinal studies are lacking. In this study, two surveys from a large general population cohort, the COVID-19 Outbreak Public Evaluation (COPE) Initiative, undertaken 147 ± 58 days apart were analyzed to determine whether the pre-existing OSA was a risk factor for the incidence of COVID-19. Of the 24,803 respondents completing the initial survey, 14,950 were negative for COVID-19; data from the follow-up survey were available for 2,325 respondents. Those with incident COVID-19 infection had a slightly higher prevalence of OSA (14.3 vs. 11.5%, p=0.068). Stratification by treatment status revealed that those untreated for their OSA were at greater risk for developing COVID-19 infection (OSA Untreated, 14.2 vs. 7.4%, p≤0.05). In a logistic regression model adjusted for comorbidities, demographic and socioeconomic factors and the interaction between vaccination status and OSA, incident COVID-19 infection was 2.15 times more likely in those with untreated OSA (aOR: 2.15, 95% CI: 1.18-3.92, p≤0.05). Stratification by treatment status revealed only untreated OSA participants were at greater risk for COVID-19 (aOR: 3.21, 95% CI: 1.25-8.23, p≤0.05). The evidence from this study confirms untreated OSA as a risk factor for acquiring COVID-19 infection and highlights the importance of actively treating and managing OSA as a preventative mechanism against COVID-19 disease.
Introduction
After the onset of the COVID-19 pandemic, it rapidly became evident that infected individuals who were older and had medical comorbidities were at greater risk for more severe disease and higher mortality (Garg, 2020). Subsequently, studies identified obstructive sleep apnea (OSA) as one of the conditions associated with a greater rate of COVID-19 infection, hospitalization, and death (Hariyanto & Kurniawan, 2021). However, virtually all studies to date have been cross-sectional or retrospective and few have been conducted in population cohort studies. Whether OSA is associated with the development of incident COVID-19 infection is yet to be determined.
The purpose of this study was to determine in a general population cohort whether OSA is a risk factor for incident COVID-19 infection. To accomplish this, we used data from The COVID-19 Outbreak Public Evaluation (COPE) Initiative (http://www.thecopeinitiative.org/), a program focused on accumulating data on public attitudes about COVID-19 and its sequelae during the pandemic from large scale, demographically representative samples.
Methods
Study Design and Participants
From March 10, 2022 to October 15, 2022, the COPE Initiative administered five successive waves of surveys focused on accumulating data on the prevalence and sequelae of COVID-19 infection. Each wave consisted of approximately 5000 unique participants who were recruited using quota-based sampling to represent population estimates for age, sex, race, and ethnicity based on the 2020 U.S. census. Surveys were conducted online by Qualtrics, LLC (Provo, Utah, and Seattle, Washington, U.S. Informed consent was obtained electronically. From September 27, 2022 to December 31, 2022, all participants were recontacted and asked to complete a follow-up survey focused on obtaining information on COVID-19 subsequent to their initial survey. Responses to the follow-up survey were limited to approximately 5,000 individuals. The mean duration between surveys was 147 ± 58 days (Minimum 43, Maximum 284).
As shown in the Figure, of the 24,803 participants initially surveyed, 4,259 participated in the follow-up survey. Of these 4,259 respondents, 2,325 indicated on their initial survey that they neither had ever tested positive for COVID-19 infection nor had developed loss of smell or taste. Therefore, they constitute the analytic cohort for this report. The study was approved by the Monash University Human Research Ethics Committee (Study #24036).
Survey Items
From the initial survey, participants self-reported their age, race, ethnicity, sex, height, weight, education level, employment status and household income. They also reported information on several current and past medical conditions by answering the question: “Have you ever been diagnosed with any of the following conditions?” In addition to OSA, opportunity was provided to endorse high blood pressure, cardiovascular disease (e.g., heart attack, stroke, angina), gastrointestinal disorder (e.g., acid reflux, ulcers, indigestion), cancer, chronic kidney disease, liver disease, sickle cell disease, chronic obstructive pulmonary disease and asthma. Possible responses to each condition were “Never”, “Yes I have in the past, but don’t have it now”, “Yes I have, but I do not regularly take medications or receiving treatment”, and “Yes I have, and I am regularly taking medications or receiving treatment”.
Symptoms of OSA were obtained from responses to the Pittsburgh Sleep Quality Index which was embedded into the initial survey and included items related to roommate or bedpartner reported “loud snoring” and “long pauses between breaths while you sleep” (Buysse et al., 1989). In addition, sleepiness was assessed from the following item in the questionnaire: During the past month, how often have you had trouble staying awake while driving, eating meals, or engaging in social activity”. Possible responses to all three items were “Not during the past month”, “less than once a week”, Once or twice a week” or “Three or more times a week”. Participants were considered to have symptoms of OSA at the time of their initial survey if they had either of the following combination of symptoms: 1) snoring “Three or more times a week”, and witnessed apnea or sleepiness “Once or twice a week”; 2) witnessed apnea and sleepiness “Once or twice a week”.
Ascertainment of past COVID-19 infection was obtained from both the initial and follow-up surveys using responses from the following questions related to COVID-19 testing or the presence of loss of taste or smell:
“Have you ever tested positive?”
“Have you experienced a problem with decreased sense of smell or taste at any point since January 2020?”
Statistical Analyses
Results for continuous or ordinal variables are reported as their respective means and standard deviations (SD) and for categorical variables as their percentages. Participants were classified as having had a COVID-19 infection if they endorsed testing positive for COVID-19 or had experienced a loss of taste or smell. They were considered to have OSA if they endorsed currently having the condition whether treated or not, or if they had two or more symptoms of OSA. Vaccination status was dichotomized as Boosted (>2 vaccinations) or Not Boosted (≤2 vaccinations). Comorbid medical conditions were defined as currently having the condition whether treated or untreated. The effect of comorbid medical conditions was evaluated by summing the number of conditions reported by the participant (minimum value 0, maximum value 9). Body mass index (BMI) was calculated using self-reported height and weight as kg/m2. Socioeconomic covariates were dichotomized as follows: employment (retired vs. not retired), education (high school or less vs. at least some college) and income in U.S. Dollars (<$50,000 vs ≧$50,000).
After stratifying by COVID-19 infection status comparisons of continuous or ordinal variables were performed using Student’s unpaired t-test; categorical variables were compared using χ2. Multivariable logistic regression was utilized to determine whether OSA was associated with COVID-19 infection. Initially, a baseline model was constructed using only OSA. Subsequently, increasingly complex models were developed by sequentially including demographic factors, boosted vaccination status, boosted vaccination status and its interaction with OSA, comorbidities, and socioeconomic factors. An additional model stratified OSA into those who were treated and those who were not. All analyses were conducted using IBM SPSS version 29 (Armonk, NY).
Results
In Table 1 is shown the association between incident COVID-19 infection status and obstructive sleep apnea, comorbid medical conditions, demographic, anthropometric and social characteristics. Of the 2,345 participants who were COVID-19 negative on the initial survey, 572 (55%) had incident COVID-19 infection (Figure). In comparison to those who remained COVID-19 infection negative at follow-up (N=1753, 45%), participants with incident COVID-19 infection were younger (60.5 ± 14.4 vs. 63.3 ± 13.0 years, p≤0.001) and had fewer medical comorbidities (1.2 ± 1.4 vs. 1.4 ± 1.4, p≤0.05). They also were less likely to be retired (50 vs. 56.4%, p≤.01) and to have a yearly income lower than the poverty level (23.8 vs. 29.0%, p≤0.01). Other characteristics, including percent receiving boosted vaccination and BMI, were not different between groups. Those with incident COVID-19 infection had a slightly higher prevalence of OSA (14.3 vs. 11.5%, p=0.068). When stratified by treatment status, those who were untreated for their OSA were at greater risk for developing COVID-19 infection (OSA Untreated, 14.2 vs. 7.4%, p≤0.05).
Participant Flow Chart
Table 2 presents the logistic regression models for incident COVID-19 infection as a function of OSA as well as the interaction of OSA and boosted vaccination status. In the baseline model and in a model adjusted only for demographic factors, the aOR for OSA as a risk factor for incident COVID-19 infection approached statistical significance (aOR: 1.31, 95% CI: 0.99-1.73, p=0.07). However, after adjustment for the interaction of OSA and boosted vaccination status as well as for comorbidities and socioeconomic factors, those with OSA were 2.15 times more likely to develop COVID-19 infection (aOR: 2.15, 95% CI: 1.18-3.92, p≤0.05). Stratification by OSA treatment status demonstrated that only those with untreated OSA were at greater risk for COVID-19 infection (aOR: 3.21, 95% CI: 1.25-8.23, p≤0.05).
Discussion
The principal finding of this longitudinal study is that untreated OSA is a risk factor for developing COVID-19 infection. Numerous previous cross-sectional investigations have observed a strong association between OSA and COVID-19 infection after adjusting for other co-morbid medical conditions including obesity (Garg, 2020). However, despite this extensive evidence associating OSA with COVID-19 infection, causation cannot be unambiguously assumed. Therefore, our finding extends these previous cross-sectional analyses by demonstrating that prospectively OSA is a risk factor for becoming infected with the SARS-CoV-19 virus.
In this study, stratification by treatment status, most likely continuous positive airway pressure (CPAP), indicated that participants who were untreated were at greater risk for COVID-19 infection related to OSA. This finding is consistent with a previous cross-sectional analysis of the COPE cohort (Quan et al., 2023), as well as other studies that also found that OSA treatment mitigated the impact of OSA on increasing risk of developing COVID-19 (Cade et al., 2020; Genzor et al., 2022). However, these observations are in contradistinction to a recent retrospective analysis of a large healthcare administrative data base in which OSA patients who had been prescribed continuous positive airway pressure developed COVID-19 infection at a greater rate than those who presumptively did not have OSA (Kendzerska et al., 2023). Prior treatment with CPAP also did not mitigate adverse outcomes in patients hospitalized with COVID-19 (Sampol et al., 2022). Thus, it is unclear whether treated individuals with OSA are protected; further studies are indicated to address this issue.
Several mechanisms may explain the increase in risk for developing COVID-19 conferred by OSA. Intermittent hypoxemia occurring during apneic or hypopneic events can promote the release of inflammatory cytokines (Ren & Hu, 2017). Intermittent hypoxemia also produces oxidative stress with release of reactive oxygen species further contributing to inflammation (Stanek et al., 2021). Introduction of the SARS-CoV-2 virus into a pre-existing inflammatory milieu could increase the likelihood of becoming infected. In addition, OSA also has been associated with cellular immune dysfunction and therefore may be a contributing factor to greater susceptibility to COVID-19 infection (Ludwig et al., 2022).
There are important limitations to this study. First, ascertainment of COVID-19 infection, OSA, and the presence of covariates were by self-report which may have resulted in misclassification. Second, only 17% of our initial participants were included in our follow-up survey which increases the likelihood that some selection bias occurred. Our finding that COVID-19 positive participants were less likely to have a comorbid condition suggests that our sample may not be representative of the entire COPE cohort and by extension, the general adult U.S. population. Nevertheless, despite a healthier cohort, we found that OSA was a risk factor for COVID-19 infection.
In conclusion, using a longitudinal cohort, OSA is a risk factor for the development of COVID-19 infection, thus confirming findings from previous cross-sectional studies. Treatment of OSA mitigated this risk, highlighting its importance in potentially preventing COVID-19. Additional studies using larger cohorts with objective ascertainment of COVID-19 infection should be performed.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
Acknowledgments
Concept and Design: SFQ
Data collection: MDW, MÉC, MEH
Data analysis and interpretation: SFQ, MDW
Drafting of the manuscript: SFQ
Critical feedback and revision of manuscript: SFQ, MDW, MÉC, LKB, LAB, MEH, MLJ, CFM, AR, RR, PV, SMWR, CAC
Footnotes
Author Approval: All authors have seen and approved the manuscript.
Conflicts of Interest: MDW reports institutional support from the US Centers for Disease Control and Prevention, National Institutes of Occupational Safety and Health, and Delta Airlines; as well as consulting fees from the Fred Hutchinson Cancer Center and the University of Pittsburgh. LKB reports institutional support from the US Centers for Disease Control and Prevention, National Institutes of Occupational Safety and Health, Delta Airlines, and the Puget Sound Pilots; as well as honorariums from the National Institutes of Occupational Safety and Health, University of Arizona and University of British Columbia. MÉC reported personal fees from Vanda Pharmaceuticals Inc., research grants or gifts to Monash University from WHOOP, Inc., Hopelab, Inc., CDC Foundation, and the Centers for Disease Control and Prevention. SMWR reported receiving grants and personal fees from Cooperative Research Centre for Alertness, Safety, and Productivity, receiving grants and institutional consultancy fees from Teva Pharma Australia and institutional consultancy fees from Vanda Pharmaceuticals, Circadian Therapeutics, BHP Billiton, and Herbert Smith Freehills. SFQ has served as a consultant for Teledoc, Bryte Foundation, Jazz Pharmaceuticals, Summus, Apnimed, and Whispersom. RR reports personal fees from SleepCycle AB; Rituals Cosmetics BV; Sonesta Hotels International, LLC; Ouraring Ltd; AdventHealth; and With Deep, LLC. CAC serves as the incumbent of an endowed professorship provided to Harvard Medical School by Cephalon, Inc. and reports institutional support for a Quality Improvement Initiative from Delta Airlines and Puget Sound Pilots; education support to Harvard Medical School Division of Sleep Medicine and support to Brigham and Women’s Hospital from: Jazz Pharmaceuticals PLC, Inc, Philips Respironics, Inc., Optum, and ResMed, Inc.; research support to Brigham and Women’s Hospital from Axome Therapeutics, Inc., Dayzz Ltd., Peter Brown and Margaret Hamburg, Regeneron Pharmaceuticals, Sanofi SA, Casey Feldman Foundation, Summus, Inc., Takeda Pharmaceutical Co., LTD, Abbaszadeh Foundation, CDC Foundation; educational funding to the Sleep and Health Education Program of the Harvard Medical School Division of Sleep Medicine from ResMed, Inc., Teva Pharmaceuticals Industries, Ltd., and Vanda Pharmaceuticals; personal royalty payments on sales of the Actiwatch-2 and Actiwatch-Spectrum devices from Philips Respironics, Inc; personal consulting fees from Axome, Inc., Bryte Foundation, With Deep, Inc. and Vanda Pharmaceuticals; honoraria from the Associated Professional Sleep Societies, LLC for the Thomas Roth Lecture of Excellence at SLEEP 2022, from the Massachusetts Medical Society for a New England Journal of Medicine Perspective article, from the National Council for Mental Wellbeing, from the National Sleep Foundation for serving as chair of the Sleep Timing and Variability Consensus Panel, for lecture fees from Teva Pharma Australia PTY Ltd. and Emory University, and for serving as an advisory board member for the Institute of Digital Media and Child Development, the Klarman Family Foundation, and the UK Biotechnology and Biological Sciences Research Council. CAC has received personal fees for serving as an expert witness on a number of civil matters, criminal matters, and arbitration cases, including those involving the following commercial and government entities: Amtrak; Bombardier, Inc.; C&J Energy Services; Dallas Police Association; Delta Airlines/Comair; Enterprise Rent-A-Car; FedEx; Greyhound Lines, Inc./Motor Coach Industries/FirstGroup America; PAR Electrical Contractors, Inc.; Puget Sound Pilots; and the San Francisco Sheriff’s Department; Schlumberger Technology Corp.; Union Pacific Railroad; United Parcel Service; Vanda Pharmaceuticals. CAC has received travel support from the Stanley Ho Medical Development Foundation for travel to Macao and Hong Kong; equity interest in Vanda Pharmaceuticals, With Deep, Inc, and Signos, Inc.; and institutional educational gifts to Brigham and Women’s Hospital from Johnson & Johnson, Mary Ann and Stanley Snider via Combined Jewish Philanthropies, Alexandra Drane, DR Capital, Harmony Biosciences, LLC, San Francisco Bar Pilots, Whoop, Inc., Harmony Biosciences LLC, Eisai Co., LTD, Idorsia Pharmaceuticals LTD, Sleep Number Corp., Apnimed, Inc., Avadel Pharmaceuticals, Bryte Foundation, f.lux Software, LLC, Stuart F. and Diana L. Quan Charitable Fund. Dr Czeisler’s interests were reviewed and are managed by the Brigham and Women’s Hospital and Mass General Brigham in accordance with their conflict-of interest policies. No other disclosures were reported.
Funding Information: This work was supported by the Centers for Disease Control and Prevention. Dr. M. Czeisler was supported by an Australian-American Fulbright Fellowship, with funding from The Kinghorn Foundation. The salary of Drs. Barger, Czeisler, Robbins and Weaver were supported, in part, by NIOSH R01 OH011773 and NHLBI R56 HL151637. Dr. Robbins also was supported in part by NHLBI K01 HL150339.
